Observation on Administration of Propofol at Different Titration Endpoints
Launched by SANQING JIN · Nov 9, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different ways of giving propofol, a commonly used medication for anesthesia, can affect patients during surgery. Researchers want to find the best way to use propofol that helps keep blood pressure stable and allows for a quicker recovery after surgery. They discovered that a slower rate of propofol infusion resulted in fewer cases of low blood pressure and less stress for patients, although there were still some cases of low blood pressure. In this study, they will compare three specific ways of giving propofol to see which method leads to the best outcomes in terms of blood pressure, anesthesia depth, and recovery speed.
To participate in this trial, you must be between 18 and 60 years old and scheduled for an elective surgery that requires general anesthesia. You should be in good health, classified as ASA I or II, which means you have no serious health issues. However, if you have certain medical conditions, such as severe heart or lung diseases, or if you are allergic to propofol, you may not be eligible. If you join the trial, you can expect careful monitoring and a focus on your comfort and recovery during and after the anesthesia process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18-60 years.
- • 2. Elective surgery with planned endotracheal intubation under general anesthesia.
- • 3. ASA classification of I or II,with heart function classified as 1 or 2.
- • 4. Body Mass Index (BMI) 18-30 kg/m².
- Exclusion Criteria:
- • 1. Severe cardiac, pulmonary, hepatic, or renal diseases (heart function classification greater than 3 / respiratory failure / liver failure / renal failure).
- • 2. Malignant arrhythmias: atrial flutter, atrial fibrillation, atrioventricular block, frequent ventricular premature beats, multifocal ventricular premature beats, ventricular premature beats R on T, ventricular flutter, and ventricular fibrillation.
- • 3. Expected difficulty with intubation, hypoalbuminemia, hypertension, or diabetes mellitus.
- • 4. Patients with a high risk of aspiration due to a full stomach, gastrointestinal obstruction, or pregnancy.
- • 5. Patients with schizophrenia, epilepsy, Parkinson's disease, intellectual disabilities, etc.
- • 6. Alcohol abusers or those who have been using sedatives or analgesics long-term.
- • 7. Allergic to propofol or its emulsion.
- • 8. Currently participating in a clinical trial that conflicts with this study.
About Sanqing Jin
Sanqing Jin is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a strong focus on developing therapeutic solutions across various therapeutic areas, Sanqing Jin collaborates with leading research institutions and healthcare professionals to design and execute rigorous clinical trials. The organization emphasizes ethical standards, patient safety, and scientific integrity, ensuring that each study contributes to a deeper understanding of disease mechanisms and the development of effective treatments. Through a robust operational framework and a commitment to excellence, Sanqing Jin aims to make a meaningful impact on global health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
SanQing Jin, MD
Principal Investigator
The Sixth Affiliated Hospital, Sun Yat-sen University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported